Activist investor Carl Icahn has dropped a threat to mount a new challenge to Illumina’s board, sparing the U.S. gene sequencing company from its second proxy contest in as many years, people familiar with the matter have told Reuters.
Sign up for our daily digest of everything you need to know about San Diego — just the essentials, every morning.
By clicking sign up, you agree to the terms.
Activist investor Carl Icahn has dropped a threat to mount a new challenge to Illumina’s board, sparing the U.S. gene sequencing company from its second proxy contest in as many years, people familiar with the matter have told Reuters.
